The development of the next generation of neuropharmaceutical drugs has been difficult to achieve. Generation and automation of high-throughput and highcontent assays to assess CNS drug effects have been formidable challenges.

Increasing fundamental knowledge of complex signal transduction pathways in the brain resulted in the identification of candidate genes for major brain disorders and the generation of targeted genetic mouse models for brain diseases. Novel opportunities are emerging.

NeuroBasic-PharmaPhenomics wants to build new rodent models of neurological and psychiatric diseases and translate pre-clinical studies of animal models into novel treatments for human patients.